Clinical Trial Update: A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Tobevibart in combination with Elebsiran for chronic hepatitis D virus infection, with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Elebsiran
• Tobevibart

Snippet

Sponsor: Vir Biotechnology, Inc. | Conditions: Viral Hepatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING